Gandara and colleagues have recently demonstrated the utility of liquid biopsies for quantifying TMB in a retrospective analysis of two large clinical trials of atezolizumab (an anti-PD-L1 CPI) for patients with advanced NSCLC where they found good concordance between blood TMB (bTMB) and tumour TMB. Here, CD274 is linked to non-small cell lung carcinoma.